Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	336.48	134.93	154.08	295.39	74.36	221.97
Short-Term Investments	217.79	278.76	428.83	282.19	410.04	224.87
Cash & Short-Term Investments	554.27	413.69	582.91	577.58	484.4	446.83
Cash Growth	18.25%	-29.03%	0.92%	19.24%	8.41%	50.07%
Accounts Receivable	45.07	38	7.6	-	-	-
Other Receivables	27.72	32.3	6.27	1.23	4.06	0.43
Receivables	72.79	70.29	13.87	1.23	4.06	0.43
Inventory	41.77	39.01	2.38	-	-	-
Prepaid Expenses	3.8	3.88	3.29	2	1.22	0.87
Restricted Cash	-	-	-	-	-	0.12
Other Current Assets	2.42	1.22	0.61	0.06	0.12	0.15
Total Current Assets	675.04	528.08	603.06	580.88	489.79	448.4
Property, Plant & Equipment	1.29	1.52	2.02	1.5	1.06	1.26
Long-Term Investments	27.22	-	119.52	29.83	5.47	-
Other Long-Term Assets	0.1	0.1	0.22	0.68	0.92	-
Total Assets	703.65	529.71	724.82	612.88	497.24	449.66

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.87	16.58	11.63	9.96	4.35	5.67
Accrued Expenses	92.75	102.34	59.68	38.97	23.67	12.76
Current Portion of Long-Term Debt	-	-	12.12	-	-	-
Current Portion of Leases	0.51	0.47	0.48	1.05	0.44	0.36
Other Current Liabilities	1.55	0.72	19.65	8.12	0.6	1.89
Total Current Liabilities	99.68	120.12	103.55	58.1	29.07	20.68
Long-Term Debt	588.12	343.91	331.57	-	-	19.9
Long-Term Leases	0.76	1.05	1.58	0.59	0.72	0.71
Total Liabilities	688.55	465.08	436.69	58.68	29.79	41.29

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,614	1,571	1,509	1,456	1,161	952.02
Retained Earnings	-1,599	-1,507	-1,221	-902.4	-693.04	-543.7
Comprehensive Income & Other	-0.14	0.45	0.16	0.22	-0.81	0.05
Total Common Equity	15.1	64.63	288.12	554.2	467.45	408.37
Shareholders' Equity	15.1	64.63	288.12	554.2	467.45	408.37
Total Liabilities & Equity	703.65	529.71	724.82	612.88	497.24	449.66

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	589.38	345.43	345.74	1.64	1.16	20.97
Net Cash (Debt)	-35.12	68.25	237.17	575.95	483.24	425.86
Net Cash Growth	-	-71.22%	-58.82%	19.19%	13.47%	53.62%
Net Cash Per Share	-0.40	0.79	2.77	8.18	7.95	7.94
Filing Date Shares Outstanding	89.3	88.2	86.02	84.97	68.44	55.01
Total Common Shares Outstanding	89.15	87.41	85.69	84.83	68.11	54.98
Working Capital	575.36	407.97	499.51	522.78	460.72	427.71
Book Value Per Share	0.17	0.74	3.36	6.53	6.86	7.43
Tangible Book Value	15.1	64.63	288.12	554.2	467.45	408.37
Tangible Book Value Per Share	0.17	0.74	3.36	6.53	6.86	7.43
Machinery	0.48	0.44	0.25	0.25	0.25	0.54
Leasehold Improvements	0.17	0.17	0.17	0.17	0.17	0.17

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Apr 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error